Antimicrobial Peptides, Skin Infections, and Atopic Dermatitis

Seminars in Cutaneous Medicine and Surgery

Volumn 27, Issue 2, 2008, Pages 144-150

  Hata, Tissa R ^a   Gallo, Richard L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHELICIDIN; CYTOKINE; DEFENSIN; DERMCIDIN; HBD 2 PROTEIN; HBD 3 PROTEIN; POLYPEPTIDE ANTIBIOTIC AGENT;

ARTICLE; ATOPIC DERMATITIS; HUMAN; INCIDENCE; INNATE IMMUNITY; MICROORGANISM; NONHUMAN; RISK FACTOR; SKIN INFECTION; STAPHYLOCOCCUS INFECTION; VIRUS INFECTION;

ANTIMICROBIAL CATIONIC PEPTIDES; DERMATITIS, ATOPIC; HUMANS; IMMUNITY, INNATE; SKIN DISEASES, INFECTIOUS;

EID: 46649110555     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sder.2008.04.002     Document Type: Article

References (119)

1. Irvine A.D., and McLean W.H. Breaking the (un)sound barrier: Filaggrin is a major gene for atopic dermatitis. J Invest Dermatol 126 (2006) 1200-1202
2. Nomura T., Sandilands A., Akiyama M., et al. Unique mutations in the filaggrin gene in Japanese patients with ichthyosis vulgaris and atopic dermatitis. J Allergy Clin Immunol 119 (2007) 434-440
3. Nomura T., Akiyama M., Sandilands A., et al. Specific filaggrin mutations cause ichthyosis vulgaris and are significantly associated with atopic dermatitis in Japan. J Invest Dermatol 128 (2008) 1436-1441
4. Sandilands A., Terron-Kwiatkowski A., Hull P.R., et al. Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. Nat Genet 39 (2007) 650-654
5. Irvine A.D. Fleshing out filaggrin phenotypes. J Invest Dermatol 127 (2007) 504-507
6. Marenholz I., Nickel R., Ruschendorf F., et al. Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march. J Allergy Clin Immunol 118 (2006) 866-871
7. Weidinger S., Illig T., Baurecht H., et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol 118 (2006) 214-219
8. Barker J.N., Palmer C.N., Zhao Y., et al. Null mutations in the filaggrin gene (FLG) determine major susceptibility to early-onset atopic dermatitis that persists into adulthood. J Invest Dermatol 127 (2007) 564-567
9. Weidinger S., Rodriguez E., Stahl C., et al. Filaggrin mutations strongly predispose to early-onset and extrinsic atopic dermatitis. J Invest Dermatol 127 (2007) 724-726
10. Palmer C.N., Ismail T., Lee S.P., et al. Filaggrin null mutations are associated with increased asthma severity in children and young adults. J Allergy Clin Immunol 120 (2007) 64-68
11. Gallo R.L., and Nizet V. Endogenous production of antimicrobial peptides in innate immunity and human disease. Curr Allergy Asthma Rep 3 (2003) 402-409
12. Nizet V., and Gallo R.L. Cathelicidins and innate defense against invasive bacterial infection. Scand J Infect Dis 35 (2003) 670-676
13. Ganz T. Defensins: Antimicrobial peptides of innate immunity. Nat Rev Immunol 3 (2003) 710-720
14. Kang S.S., Kauls L.S., and Gaspari A.A. Toll-like receptors: applications to dermatologic disease. J Am Acad Dermatol 54 (2006) 951-983 quiz 983-986
15. Janeway Jr. C.A., and Medzhitov R. Innate immune recognition. Annu Rev Immunol 20 (2002) 197-216
16. Medzhitov R., and Janeway Jr. C.A. Innate immunity: Impact on the adaptive immune response. Curr Opin Immunol 9 (1997) 4-9
17. Mempel M., Voelcker V., Kollisch G., et al. Toll-like receptor expression in human keratinocytes: Nuclear factor kappaB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent. J Invest Dermatol 121 (2003) 1389-1396
18. Kollisch G., Kalali B.N., Voelcker V., et al. Various members of the Toll-like receptor family contribute to the innate immune response of human epidermal keratinocytes. Immunology 114 (2005) 531-541
19. Gay N.J., and Keith F.J. Drosophila Toll and IL-1 receptor. Nature 351 (1991) 355-356
20. Leulier F., and Lemaitre B. Toll-like receptors-taking an evolutionary approach. Nat Rev Genet 9 (2008) 165-178
21. Hawlisch H., and Kohl J. Complement and Toll-like receptors: Key regulators of adaptive immune responses. Mol Immunol 43 (2006) 13-21
22. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430 (2004) 257-263
23. Ahmad-Nejad P., Mrabet-Dahbi S., Breuer K., et al. The toll-like receptor 2 R753Q polymorphism defines a subgroup of patients with atopic dermatitis having severe phenotype. J Allergy Clin Immunol 113 (2004) 565-567
24. Schittek B., Hipfel R., Sauer B., et al. Dermcidin: a novel human antibiotic peptide secreted by sweat glands. Nat Immunol 2 (2001) 1133-1137
25. Weidinger S., Klopp N., Rummler L., et al. Association of NOD1 polymorphisms with atopic eczema and related phenotypes. J Allergy Clin Immunol 116 (2005) 177-184
26. Schroder N.W., Morath S., Alexander C., et al. Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J Biol Chem 278 (2003) 15587-15594
27. Dziarski R. Recognition of bacterial peptidoglycan by the innate immune system. Cell Mol Life Sci 60 (2003) 1793-1804
28. Zdolsek H.A., and Jenmalm M.C. Reduced levels of soluble CD14 in atopic children. Clin Exp Allergy 34 (2004) 532-539
29. Rothenbacher D., Weyermann M., Beermann C., et al. Breastfeeding, soluble CD14 concentration in breast milk and risk of atopic dermatitis and asthma in early childhood: birth cohort study. Clin Exp Allergy 35 (2005) 1014-1021
30. Jones C.A., Holloway J.A., Popplewell E.J., et al. Reduced soluble CD14 levels in amniotic fluid and breast milk are associated with the subsequent development of atopy, eczema, or both. J Allergy Clin Immunol 109 (2002) 858-866
31. Steiner H., Hultmark D., Engstrom A., et al. Sequence and specificity of two antibacterial proteins involved in insect immunity. Nature 292 (1981) 246-248
32. Ganz T., Selsted M.E., Szklarek D., et al. Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest 76 (1985) 1427-1435
33. Mallow E.B., Harris A., Salzman N., et al. Human enteric defensins. Gene structure and developmental expression. J Biol Chem 271 (1996) 4038-4045
34. Cole A.M., Hong T., Boo L.M., et al. Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc Natl Acad Sci U S A 99 (2002) 1813-1818
35. Fulton C., Anderson G.M., Zasloff M., et al. Expression of natural peptide antibiotics in human skin. Lancet 350 (1997) 1750-1751
36. Ali R.S., Falconer A., Ikram M., et al. Expression of the peptide antibiotics human beta defensin-1 and human beta defensin-2 in normal human skin. J Invest Dermatol 117 (2001) 106-111
37. Zhao C., Wang I., and Lehrer R.I. Widespread expression of beta-defensin hBD-1 in human secretory glands and epithelial cells. FEBS Lett 396 (1996) 319-322
38. Liu A.Y., Destoumieux D., Wong A.V., et al. Human beta-defensin-2 production in keratinocytes is regulated by interleukin-1, bacteria, and the state of differentiation. J Invest Dermatol 118 (2002) 275-281
39. Harder J., Bartels J., Christophers E., et al. Isolation and characterization of human beta -defensin-3, a novel human inducible peptide antibiotic. J Biol Chem 276 (2001) 5707-5713
40. Harder J., Meyer-Hoffert U., Wehkamp K., et al. Differential gene induction of human beta-defensins (hBD-1, -2, -3, and -4) in keratinocytes is inhibited by retinoic acid. J Invest Dermatol 123 (2004) 522-529
41. Harder J., Bartels J., Christophers E., et al. A peptide antibiotic from human skin. Nature 387 (1997) 861
42. Ericksen B., Wu Z., Lu W., et al. Antibacterial activity and specificity of the six human {alpha}-defensins. Antimicrob Agents Chemother 49 (2005) 269-275
43. Wilde C.G., Griffith J.E., Marra M.N., et al. Purification and characterization of human neutrophil peptide 4, a novel member of the defensin family. J Biol Chem 264 (1989) 11200-11203
44. Hoover D.M., Wu Z., Tucker K., et al. Antimicrobial characterization of human beta-defensin 3 derivatives. Antimicrob Agents Chemother 47 (2003) 2804-2809
45. Bastian A., and Schafer H. Human alpha-defensin 1 (HNP-1) inhibits adenoviral infection in vitro. Regul Pept 101 (2001) 157-161
46. Buck C.B., Day P.M., Thompson C.D., et al. Human alpha-defensins block papillomavirus infection. Proc Natl Acad Sci U S A 103 (2006) 1516-1521
47. Sun L., Finnegan C.M., Kish-Catalone T., et al. Human beta-defensins suppress human immunodeficiency virus infection: Potential role in mucosal protection. J Virol 79 (2005) 14318-14329
48. Chang T.L., Vargas Jr. J., DelPortillo A., et al. Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. J Clin Invest 115 (2005) 765-773
49. Hazrati E., Galen B., Lu W., et al. Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J Immunol 177 (2006) 8658-8666
50. Chaly Y.V., Paleolog E.M., Kolesnikova T.S., et al. Neutrophil alpha-defensin human neutrophil peptide modulates cytokine production in human monocytes and adhesion molecule expression in endothelial cells. Eur Cytokine Netw 11 (2000) 257-266
51. van Wetering S., Mannesse-Lazeroms S.P., van Sterkenburg M.A., et al. Neutrophil defensins stimulate the release of cytokines by airway epithelial cells: modulation by dexamethasone. Inflamm Res 51 (2002) 8-15
52. Van Wetering S., Mannesse-Lazeroms S.P., Van Sterkenburg M.A., et al. Effect of defensins on interleukin-8 synthesis in airway epithelial cells. Am J Physiol 272 (1997) L888-L896
53. Niyonsaba F., Ushio H., Nagaoka I., et al. The human beta-defensins (-1, -2, -3, -4) and cathelicidin LL-37 induce IL-18 secretion through p38 and ERK MAPK activation in primary human keratinocytes. J Immunol 175 (2005) 1776-1784
54. Zanetti M., Gennaro R., and Romeo D. Cathelicidins: A novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett 374 (1995) 1-5
55. Ritonja A., Kopitar M., Jerala R., et al. Primary structure of a new cysteine proteinase inhibitor from pig leucocytes. FEBS Lett 255 (1989) 211-214
56. Zelezetsky I., Pontillo A., Puzzi L., et al. Evolution of the primate cathelicidin. Correlation between structural variations and antimicrobial activity. J Biol Chem 281 (2006) 19861-19871
57. Braff M.H., Di Nardo A., and Gallo R.L. Keratinocytes store the antimicrobial peptide cathelicidin in lamellar bodies. J Invest Dermatol 124 (2005) 394-400
58. Murakami M., Lopez-Garcia B., Braff M., et al. Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense. J Immunol 172 (2004) 3070-3077
59. Yamasaki K., Schauber J., Coda A., et al. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J 20 (2006) 2068-2080
60. Frohm M., Agerberth B., Ahangari G., et al. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J Biol Chem 272 (1997) 15258-15263
61. Schauber J., Dorschner R.A., Coda A.B., et al. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest 117 (2007) 803-811
62. Schauber J., Dorschner R.A., Yamasaki K., et al. Control of the innate epithelial antimicrobial response is cell-type specific and dependent on relevant microenvironmental stimuli. Immunology 118 (2006) 509-519
63. Liu P.T., Stenger S., Li H., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311 (2006) 1770-1773
64. Peyssonaux C., and Johnson R.S. An unexpected role for hypoxic response: Oxygenation and inflammation. Cell Cycle 3 (2004) 168-171
65. Gallo R.L., Kim K.J., Bernfield M., et al. Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse. J Biol Chem 272 (1997) 13088-13093
66. Agerberth B., Charo J., Werr J., et al. The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 96 (2000) 3086-3093
67. Di Nardo A., Vitiello A., and Gallo R.L. Cutting edge: Mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J Immunol 170 (2003) 2274-2278
68. Borregaard N., and Cowland J.B. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 89 (1997) 3503-3521
69. Frohm M., Gunne H., Bergman A.C., et al. Biochemical and antibacterial analysis of human wound and blister fluid. Eur J Biochem 237 (1996) 86-92
70. Agerberth B., Grunewald J., Castanos-Velez E., et al. Antibacterial components in bronchoalveolar lavage fluid from healthy individuals and sarcoidosis patients. Am J Respir Crit Care Med 160 (1999) 283-290
71. Murakami M., Ohtake T., Dorschner R.A., et al. Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin. J Invest Dermatol 119 (2002) 1090-1095
72. Murakami M., Ohtake T., Dorschner R.A., et al. Cathelicidin antimicrobial peptides are expressed in salivary glands and saliva. J Dent Res 81 (2002) 845-850
73. Marchini G., Lindow S., Brismar H., et al. The newborn infant is protected by an innate antimicrobial barrier: peptide antibiotics are present in the skin and vernix caseosa. Br J Dermatol 147 (2002) 1127-1134
74. Henzler Wildman K.A., Lee D.K., and Ramamoorthy A. Mechanism of lipid bilayer disruption by the human antimicrobial peptide LL-37. Biochemistry 42 (2003) 6545-6558
75. Gutsmann T., Hagge S.O., Larrick J.W., et al. Interaction of CAP18-derived peptides with membranes made from endotoxins or phospholipids. Biophys J 80 (2001) 2935-2945
76. Nizet V., Ohtake T., Lauth X., et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 414 (2001) 454-457
77. Rosenberger C.M., Gallo R.L., and Finlay B.B. Interplay between antibacterial effectors: A macrophage antimicrobial peptide impairs intracellular Salmonella replication. Proc Natl Acad Sci U S A 101 (2004) 2422-2427
78. Iimura M., Gallo R.L., Hase K., et al. Cathelicidin mediates innate intestinal defense against colonization with epithelial adherent bacterial pathogens. J Immunol 174 (2005) 4901-4907
79. Howell M.D., Jones J.F., Kisich K.O., et al. Selective killing of vaccinia virus by LL-37: Implications for eczema vaccinatum. J Immunol 172 (2004) 1763-1767
80. Lopez-Garcia B., Lee P.H., Yamasaki K., et al. Anti-fungal activity of cathelicidins and their potential role in Candida albicans skin infection. J Invest Dermatol 125 (2005) 108-115
81. Dorschner R.A., Lopez-Garcia B., Massie J., et al. Innate immune defense of the nail unit by antimicrobial peptides. J Am Acad Dermatol 50 (2004) 343-348
82. Braff M.H., Hawkins M.A., Di Nardo A., et al. Structure-function relationships among human cathelicidin peptides: Dissociation of antimicrobial properties from host immunostimulatory activities. J Immunol 174 (2005) 4271-4278
83. Tjabringa G.S., Aarbiou J., Ninaber D.K., et al. The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J Immunol 171 (2003) 6690-6696
84. Niyonsaba F., Ushio H., Nakano N., et al. Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J Invest Dermatol 127 (2007) 594-604
85. De Y., Chen Q., Schmidt A.P., et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 192 (2000) 1069-1074
86. Rieg S., Garbe C., Sauer B., et al. Dermcidin is constitutively produced by eccrine sweat glands and is not induced in epidermal cells under inflammatory skin conditions. Br J Dermatol 151 (2004) 534-539
87. Baechle D., Flad T., Cansier A., et al. Cathepsin D is present in human eccrine sweat and involved in the postsecretory processing of the antimicrobial peptide DCD-1L. J Biol Chem 281 (2006) 5406-5415
88. Lai Y.P., Peng Y.F., Zuo Y., et al. Functional and structural characterization of recombinant dermcidin-1L, a human antimicrobial peptide. Biochem Biophys Res Commun 328 (2005) 243-250
89. Lin Y.T., Wang C.T., and Chiang B.L. Role of bacterial pathogens in atopic dermatitis. Clin Rev Allergy Immunol 33 (2007) 167-177
90. Williams R.E., Gibson A.G., Aitchison T.C., et al. Assessment of a contact-plate sampling technique and subsequent quantitative bacterial studies in atopic dermatitis. Br J Dermatol 123 (1990) 493-501
91. Leung D.Y. Infection in atopic dermatitis. Curr Opin Pediatr 15 (2003) 399-404
92. Grice K., Sattar H., Baker H., et al. The relationship of transepidermal water loss to skin temperature in psoriasis and eczema. J Invest Dermatol 64 (1975) 313-315
93. Ong P.Y., Ohtake T., Brandt C., et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 347 (2002) 1151-1160
94. Nomura I., Goleva E., Howell M.D., et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 171 (2003) 3262-3269
95. Howell M.D., Novak N., Bieber T., et al. Interleukin-10 downregulates anti-microbial peptide expression in atopic dermatitis. J Invest Dermatol 125 (2005) 738-745
96. Homey B., Steinhoff M., Ruzicka T., et al. Cytokines and chemokines orchestrate atopic skin inflammation. J Allergy Clin Immunol 118 (2006) 178-189
97. Jeong C.W., Ahn K.S., Rho N.K., et al. Differential in vivo cytokine mRNA expression in lesional skin of intrinsic vs. extrinsic atopic dermatitis patients using semiquantitative RT-PCR: Clin Exp Allergy 33 (2003) 1717-1724
98. Kaburagi Y., Shimada Y., Nagaoka T., et al. Enhanced production of CC-chemokines (RANTES, MCP-1, MIP-1alpha MIP-1beta, and eotaxin) in patients with atopic dermatitis. Arch Dermatol Res 293 (2001) 350-355
99. Campbell J.J., and Butcher E.C. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr Opin Immunol 12 (2000) 336-341
100. Howell M.D., Gallo R.L., Boguniewicz M., et al. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity 24 (2006) 341-348
101. Howell M.D., Boguniewicz M., Pastore S., et al. Mechanism of HBD-3 deficiency in atopic dermatitis. Clin Immunol 121 (2006) 332-338
102. Nishijima S., Namura S., Kawai S., et al. Staphylococcus aureus on hand surface and nasal carriage in patients with atopic dermatitis. J Am Acad Dermatol 32 (1995) 677-679
103. Postlethwaite A.E., Holness M.A., Katai H., et al. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 90 (1992) 1479-1485
104. Grassegger A., and Hopfl R. Significance of the cytokine interferon gamma in clinical dermatology. Clin Exp Dermatol 29 (2004) 584-588
105. Machura E., Mazur B., Golemiec E., et al. Staphylococcus aureus skin colonization in atopic dermatitis children is associated with decreased IFN-gamma production by peripheral blood CD4+ and CD8+ T cells. Pediatr Allergy Immunol 19 (2008) 37-45
106. Rieg S., Steffen H., Seeber S., et al. Deficiency of dermcidin-derived antimicrobial peptides in sweat of patients with atopic dermatitis correlates with an impaired innate defense of human skin in vivo. J Immunol 174 (2005) 8003-8010
107. Cho S.H., Strickland I., Tomkinson A., et al. Preferential binding of Staphylococcus aureus to skin sites of Th2-mediated inflammation in a murine model. J Invest Dermatol 116 (2001) 658-663
108. Cho S.H., Strickland I., Boguniewicz M., et al. Fibronectin and fibrinogen contribute to the enhanced binding of Staphylococcus aureus to atopic skin. J Allergy Clin Immunol 108 (2001) 269-274
109. Wann E.R., Gurusiddappa S., and Hook M. The fibronectin-binding MSCRAMM FnbpA of Staphylococcus aureus is a bifunctional protein that also binds to fibrinogen. J Biol Chem 275 (2000) 13863-13871
110. Plaut M., and Tinkle S.S. Risks of smallpox vaccination: 200 years after Jenner. J Allergy Clin Immunol 112 (2003) 683-685
111. Bicknell W.J. The case for voluntary smallpox vaccination. N Engl J Med 346 (2002) 1323-1325
112. Wharton M., Strikas R.A., Harpaz R., et al. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 52 (2003) 1-16
113. Marris E. Dramatic rescue relieves rare case of smallpox infection. Nat Med 13 (2007) 517
114. Wollenberg A., Wetzel S., Burgdorf W.H., et al. Viral infections in atopic dermatitis: pathogenic aspects and clinical management. J Allergy Clin Immunol 112 (2003) 667-674
115. Peng W.M., Jenneck C., Bussmann C., et al. Risk factors of atopic dermatitis patients for eczema herpeticum. J Invest Dermatol 127 (2007) 1261-1263
116. Howell M.D., Wollenberg A., Gallo R.L., et al. Cathelicidin deficiency predisposes to eczema herpeticum. J Allergy Clin Immunol 117 (2006) 836-841
117. Uchida Y., Kurasawa K., Nakajima H., et al. Increase of dendritic cells of type 2 (DC2) by altered response to IL-4 in atopic patients. J Allergy Clin Immunol 108 (2001) 1005-1011
118. Wollenberg A., Wagner M., Gunther S., et al. Plasmacytoid dendritic cells: A new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 119 (2002) 1096-1102
119. Rissoan M.C., Soumelis V., Kadowaki N., et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 283 (1999) 1183-1186